Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line
Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of ...
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...
BioSpace10h
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Opinion
Hosted on MSN23hOpinion
Top Analyst Reports for Home Depot, Booking & Eaton
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...